<DOC>
	<DOC>NCT01085123</DOC>
	<brief_summary>The purpose of this study is to determine the central 5-HT1B receptor occupancy of ZOMIG® Rapimelt (zolmitriptan) in healthy male volunteers.</brief_summary>
	<brief_title>Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Zolmitriptan</mesh_term>
	<criteria>Body mass index between ≥19 and ≤30 kg/m2. A history or presence of neurological, haematological, psychiatric, gastrointestinal, hepatic, pulmonary, renal disease Use of drugs that induce the liver drug metabolising enzymes within 4 weeks before first PET</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Migraine</keyword>
	<keyword>ZOMIG® Rapimelt</keyword>
</DOC>